Innocan Pharma’s LPT-CBD: A Promising Pain Relief Solution
Innocan Pharma Corporation has emerged as an innovative frontrunner in the field of pharmaceutical solutions, particularly in addressing pain management for animals. The recent findings from their multi-year compassionate therapy initiative are particularly exciting. Using liposomal cannabidiol (LPT-CBD) injections, Innocan has been able to provide significant relief from osteoarthritis pain in dogs. This breakthrough therapy offers a compelling option for those seeking alternatives to traditional pain relief methods.
Long-Lasting Relief for Canine Osteoarthritis
The administration of LPT-CBD showcases remarkable effectiveness in alleviating discomfort in dogs suffering from osteoarthritis. Owners of dogs who have not found success with conventional non-steroidal anti-inflammatory drugs (NSAIDs) are increasingly turning to this therapy. The reports resulting from these repeated LPT-CBD injections indicate not only considerable pain reduction but also an enhancement in the overall mobility of the dogs involved in the treatment.
Positive Outcomes Observed in Treatment Duration
Currently, among the ongoing cases, two dogs that have undergone LPT-CBD treatment for periods ranging from two to 2.5 years have shown remarkable improvement in their quality of life. Such positive outcomes reinforce the capability of LPT-CBD to deliver sustained relief while allowing sufferers to regain their vitality and happiness.
Experts Weigh In on Efficacy
Professor Chezy Barenholz, the Chief Scientific Officer at Innocan Pharma, expressed his enthusiasm regarding these findings. He noted that the long-term effects of LPT-CBD injections hold substantial promise for chronic pain management in animals. This perspective aligns with the broader vision of Innocan to not only improve the lives of animals but also to extend these benefits to humans in the future.
Commitment to Veterinary Medicine
Dr. Eyal Kalo, the R&D Director, shared insights into how this compassionate therapy emphasizes their commitment to obtaining FDA approval under the Center for Veterinary Medicine (CVM) for the use of LPT-CBD in treating chronic pain in dogs. This determination reflects Innocan's strategic direction toward not just advancing therapy options but ensuring regulatory standards are met.
About Innocan Pharma Corporation
Innocan is not just an innovator in pain management; its influence stretches across pharmaceutical and wellness products. Their development of a CBD-loaded liposome delivery system highlights their commitment to providing effective dosage and sustained relief without the need for opioids. The wellness sector of Innocan is also noteworthy, with a diverse range of self-care and beauty products designed to enhance quality of life.
Contact Information
Those interested in learning more about Innocan Pharma Corporation can reach out directly. The CEO, Iris Bincovich, can be contacted at the following numbers:
- +1 5162104025
- +972-54-3012842
- +442037699377
Frequently Asked Questions
What is LPT-CBD?
LPT-CBD is a liposomal formulation of cannabidiol designed to provide targeted pain relief, particularly for conditions like osteoarthritis in pets.
How does LPT-CBD work?
The therapy enhances bioavailability and minimizes first-pass metabolism, leading to a more effective pain management solution for dogs.
What results have been observed in dogs?
Dogs treated with LPT-CBD have experienced significant pain relief and improved mobility over extended treatment periods, often lasting for years.
Who oversees the development of LPT-CBD?
Innocan Pharma, under the guidance of its Chief Scientific Officer and R&D Director, is responsible for the research and development of LPT-CBD.
What future plans does Innocan have for LPT-CBD?
Innocan aims to advance FDA approval for LPT-CBD for use in treating chronic pain in dogs, with the potential to explore applications for human medicine.
